MoST
09 Dec 2020
Trial Summary
This study aims to screen patients with advanced cancer and unmet clinical needs for actionable biomarkers to be used to guide therapy.
Acronym:
MoST
ACTRN/NCT /ethics:
ACTRN12616000908437
Scientific title:
The Cancer Molecular Screening and Therapeutics (MoST) Program – A framework protocol for multiple, parallel, signal-seeking clinical studies of novel molecularly targeted therapies for patients with advanced cancer and unmet clinical need.
Sponsor / Cooperative group:
The University of Sydney
Trial & Patient Characteristics
| Cancer Type | All cancers |
|---|---|
| Trial Type | Early detection, diagnosis, prognosis |
| Phase | All phases |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Recurrent or Locally Advanced; Metastatic or Widespread |
| Anticipated Start Date | 2016-09-09 |
| Anticipated End Date | 2020-09-11 |
Participating Hospitals
| Hospital | Royal Adelaide Hospital |
|---|---|
| Clinical Trial Coordinator | Anne Milton |
| anne.milton@sa.gov.au | |
| Phone | 08 7074 2342 |
| Principal Investigator | Professor Michael Brown |
| Recruitment Status | Recruiting |
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alison Richards |
| Alison.Richards@sa.gov.au | |
| Phone | 08 8206 4835 |
| Principal Investigator | Dr Chris Karapetis |
| Recruitment Status | Recruiting |